This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...
Legacy Community Health, Houston Methodist, elected officials and community leaders celebrate the grand opening of the new Legacy Acres Homes Clinic with a ribbon-cutting ceremony in Houston. Photo ...
The stock options have a ten-year term, and an exercise price of $18.06 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options ...
Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic, metabolic, and rare diseases, today announced that ...
Frederick, MD, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Frederick Breathe Free Sinus & Allergy Centers announced today that Jamie Oberman, MD, FACS, EMBA, has been recognized as a 2026 Castle Connolly Top ...
Two oral presentations at AHA Hypertension 2026 will highlight the substantial antihypertensive efficacy of aprocitentan in two hypertension populations from the PRECISION study: patients with obesity ...
Honoring Dr. Susan Steen's Legacy The appointment also gives GAP the opportunity to recognize the contributions of Dr. Susan Steen, who has led Axiom Brain Health for decades and whose expertise and ...
Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic ...
Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging. Currently executing Phase 3 readiness activities in ...
ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET. Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic can ...
“This milestone is an important step forward for the cadisegliatin program,” said Thomas Strack, MD, Chief Medical Officer of vTv Therapeutics. “Our focus now is maintaining the quality and integrity ...
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results